AACR 2019

March 29, 2019

The Epic Sciences team attended AACR Annual Meeting - Booth #4455 - in Atlanta, GA from March 29 - April 3, 2019.

Following are the AACR 2019 posters and presentations:

Oral Presentation:

Title:  Liquid Biopsies: From Validation to Clinical Utility

Session Description: Discussion of the development and clinical application of validated circulating tumor cell (CTC) and cell-free DNA assays to determine prognosis, predict response to treatment, identify mechanisms of resistance to guide future treatment, and assess drug effects.

Chairperson & Presentation: Howard I. Scher, Memorial Sloan Kettering Cancer Center; Predictive biomarkers in circulating tumor cells to direct management of metastatic castration-resistant prostate cancer (mCRPC)

Session Date and Time:  April 1, 2019, 2:05 pm - 2:30 pm ET

Poster Presentations:

Title: HER2, AR protein expression and chromosomal instability in circulating tumor cells (CTCs) of metastatic breast cancer (MBC) patients (pts)

Session Category and Title: Clinical Research: Current Developments in Non-invasive Biomarkers for Assessment of Cancer 1

Session Date and Time: Sunday, March 31, 2019 1:00 pm – 5:00 pm ET

Title: Genomic instability as a marker of poor prognosis in advanced prostate cancer: Subclonal insights from whole-genome sequencing of single circulating tumor cells

Session Category and Title: Clinical Research: Current Developments in Non-invasive Biomarkers for Assessment of Cancer 1

Session Date and Time: Sunday, March 31, 2019, 1:00 pm – 5:00 pm ET

Title: Characterization of SLFN11 protein expression in circulating tumor cells (CTCs) of patients with metastatic castration-resistant prostate cancer (mCRPC) prior to platinum based chemotherapy

Session Category and Title: Clinical Research: Circulating and Cell-free Biomarkers for Diagnosis and Monitoring of Cancer 2

Session Date and Time: Monday, April 1, 2019, 8:00 am – 12:00 pm ET

Title: Comparison of the Epic CTC HRD assay vs. tumor DDR mutations in metastatic castration-resistant prostate cancer (mCRPC) patients (pts)

Session Category and Title: Clinical Research: Circulating and Cell-free Biomarkers for Diagnosis and Monitoring of Cancer 3

Session Date and Time: Monday, April 1, 2019, 1:00 pm – 5:00 pm ET

Title: SLFN11 and EZH2 protein expression and localization in circulating tumor cells to predict response or resistance to DNA damaging therapies in small cell lung cancer

Session Category and Title: Circulating and Cell-free Biomarkers for Diagnosis and Monitoring of Cancer 3

Session Date and Time: Monday, April 1, 2019, 1:00 pm – 5:00 pm ET

Title: Single-cell analyses reveal increasing intratumoral heterogeneity as an essential component of treatment resistance in small-cell lung cancer

Session Category and Title: Tumor Biology: Tumor Evolution and Heterogeneity 1

Session Date and Time: Tuesday, April 2, 2019 8:00 am – 12:00 pm ET

Title: Evaluation of pharmacokinetics of proxalutamide, a novel androgen receptor antagonist, in treatment for mCRPC patients via CTC enumeration and AR biomarker analysis

Session Category and Title: Experimental and Molecular Therapeutics: Pharmacokinetics and Pharmacodynamics/Preclinical Toxicology

Session Date and Time: Tuesday, April 2, 2019, 1:00 pm – 5:00 pm ET

Title: Simultaneous quantification of activated immune cells and PD-L1 expressing circulating tumor cells (CTCs) in peripheral blood of cancer patients receiving checkpoint inhibitor therapy

Session Category and Title: Immunology: Biomarkers and Immune Monitoring

Session Date and Time: Tuesday, April 2, 2019, 1:00 pm – 5:00 pm ET